title: Current status of intraperitoneal therapy for ovarian cancer.
abstract: Recent attention has focused on evaluating those clinical situations in which intraperitoneal drug delivery may be an appropriate treatment option for patients with ovarian cancer. When employed as a second-line strategy, approximately 20% to 30% of patients with small-volume residual disease (microscopic, largest tumor mass < or = 0.5 to 1 cm in maximum diameter) at initiation of treatment are expected to achieve a surgically documented complete response with a variety of organoplatinum-based intraperitoneal regimens. However, responses are rarely observed in such patients who have failed to demonstrate tumor sensitivity to systemically delivered organoplatinum drugs, despite the presence of small-volume residual disease. Investigators at several centers are currently exploring a possible role for regional drug delivery in the initial management of selected patients (ie, small-volume disease) with ovarian cancer. A recently reported trial of intraperitoneal taxol suggests this may be an ideal drug for regional therapy of ovarian cancer due to a major pharmacokinetic advantage associated with this route of drug delivery.
authors.affiliation: Department of Hepatology/Medical Oncology, Cleveland Clinic Foundation, OH 44195.
authors.forename: M
authors.initials: M
authors.lastname: Markman
mesh_terms: D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010052:Ovariectomy / Q000592:standards; D016879:Salvage Therapy / Q000379:methods / Q000592:standards; D015996:Survival Rate
chemical_list: D007372:Interferons; D002945:Cisplatin